The Institute of Traditional Chinese Medicine of the Chinese Academy of Traditional Chinese Medicine completes the six types of new medicines of traditional Chinese medicine protection granules technology transfer

School of Science and Technology of Chinese Medicine Sciences

Public account ID: CACMS1955

focus on

On July 7, the Institute of Traditional Chinese Medicine of the Chinese Academy of Traditional Chinese Medicine and Zhuhai Tianda Traditional Chinese Medicine Research and Development Co., Ltd. completed the transfer signing ceremony of the six new drugs of traditional Chinese medicine. Yang Hongjun, deputy dean of the Chinese Academy of Traditional Chinese Medicine, attended the ceremony. Zhang Huamin, Secretary of the Party Committee of the Institute of Traditional Chinese Medicine, and Wang Weiping, deputy general manager of Tianda Group, signed a promotional particle transfer agreement. The meeting was chaired by Liu An, director of the Science and Technology Development Division of the Institute of Traditional Chinese Medicine, and Yang Yuhua, deputy general manager of Tianda Traditional Chinese Medicine Research and Development Co., Ltd., and members of the Baoxin Granules Project Team attended the signing ceremony.

Yang Hongjun pointed out that the transformation of scientific research results is the ultimate goal of scientific research, especially the scientific research results towards major clinical needs can be transformed and will provide a strong guarantee for people's health. It is hoped that through the cooperation with Tianda Pharmaceuticals, the market demand is the lead, and the industry layout of Tianda will accurately and effectively promote the transformation of the original research and innovative scientific research results of the Institute of Traditional Chinese Medicine. At the same time, with the development opportunities of the Guangdong -Hong Kong -Macao Greater Bay Area, it also explores a new path for Chinese medicine.

Zhang Huamin introduced the overall situation of the Institute of Traditional Chinese Medicine and the research and development process of protecting the granules, and said that he hoped that the two parties could continue to strengthen the research and development of Chinese medicine innovation drugs and classic famous prescriptions through the bridge of the heart granular project, and give full play to the Institute of Traditional Chinese Medicine Research Institute. The advantages of disciplines, talents and platforms, layout in full -chain, all -round and systematic cooperation in the full -chain of traditional Chinese medicine in Chinese medicine quality control, application -oriented key technologies, large health industries and traditional Chinese medicine information databases.

Baoxin particles are the six new types of traditional Chinese medicine in the Institute of Traditional Chinese Medicine. Since 2008, the research team of Researcher Shen Xin started research. After more than ten years of accumulation and precipitation, they have rich experience and research foundation, and have obtained major new drugs respectively. Creation -Danqi Baoxin Fang treats clinical research funding for topics such as chronic heart failure optimization research, new Chinese medicine new drugs based on big data, and the development of key technologies and variety development, and obtained clinical approval certificates in October 2018. While the research and development of Baochen particles meets the actual needs of modern clinical clinical, the overall design is based on the principle of respecting traditional craftsmanship and human use experience. After fully considering the compliance of clinical experiments and the rhythm of the life of modern crowd after listing, it is carefully considered. Design usage dosage and sensory characteristics.

The Institute of Traditional Chinese Medicine pays attention to the research and development of new drugs. At present, there are 33 new drugs. The dual -hydrogen hydrogen artemisinin tablets, Huanglian detoxification pills, Shuyan tablets, protective granules, Baili fragrant medicine tea, etc. have obtained the national new drug clinical approval. The in -depth participation in the development of anti -new coronary pneumonia Chinese medicines -clear lung detoxification particles and dampness and defective particles have been approved to be listed, and thus won the title of "National Science and Technology System Anti -New Crown Pneumonia Epidemium".

Author: Tian Jixiang, Institute of Chinese Medicine Research Institute

Edit: Sun Baixiang

- END -